Zevra Therapeutics, Inc. (ZVRA)
| Market Cap | 627.21M +32.5% |
| Revenue (ttm) | 122.29M +201.3% |
| Net Income | 117.00M |
| EPS | 1.98 |
| Shares Out | 59.12M |
| PE Ratio | 5.35 |
| Forward PE | 15.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,137,592 |
| Open | 11.14 |
| Previous Close | 11.17 |
| Day's Range | 10.36 - 11.18 |
| 52-Week Range | 7.16 - 13.16 |
| Beta | 0.89 |
| Analysts | Strong Buy |
| Price Target | 23.00 (+116.78%) |
| Earnings Date | May 6, 2026 |
About ZVRA
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical tr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ZVRA stock is "Strong Buy." The 12-month stock price target is $23.0, which is an increase of 116.78% from the latest price.
News
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living w...
Zevra Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
A focused strategic plan has driven operational streamlining, a headquarters move to Boston, and targeted growth in both U.S. and global markets. AI-powered patient identification and robust regulatory progress support expanding access and pipeline acceleration, with variability in patient enrollment expected.
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseas...
Zevra Therapeutics price target raised to $25 from $23 at Guggenheim
Guggenheim analyst Eddie Hickman raised the firm’s price target on Zevra Therapeutics (ZVRA) to $25 from $23 and keeps a Buy rating on the shares. The firm expects growth to…
Zevra Therapeutics reports Q1 EPS 60c, consensus 8c
Reports Q1 revenue $36.2M, consensus $31.96M. In Q1, the company received $40.5M of the $45M in net proceeds from the sale of the SDX portfolio. “Our results demonstrate the differentiated…
Zevra Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw 78% revenue growth, strong net income, and debt-free status driven by MIPLYFFA's U.S. launch and global expansion, SDX asset sale, and robust pipeline progress. MIPLYFFA now reaches about half of diagnosed U.S. NPC patients, with continued growth expected.
Zevra Therapeutics Earnings release: Q1 2026
Zevra Therapeutics released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Zevra Therapeutics Quarterly report: Q1 2026
Zevra Therapeutics has published its Q1 2026 quarterly earnings report on May 6, 2026.
Zevra Reports First Quarter 2026 Financial Results and Corporate Update
Q1 2026 net revenue of $36.2 million , a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 mil...
Zevra Therapeutics Proxy statement: Proxy filing
Zevra Therapeutics filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Zevra Therapeutics Proxy statement: Proxy filing
Zevra Therapeutics filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Zevra Therapeutics Slides: Corporate presentation
Zevra Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 6, 2026.
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare dise...
Zevra Therapeutics sells SDX portfolio to Commave for $50M
Zevra Therapeutics (ZVRA) announced an agreement under which Commave Therapeutics will purchase Zevra’s serdexmethylphenidate portfolio, including AZSTARYS and KP1077, for $50 million. Zevra and Comma...
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare dise...
Zevra Therapeutics initiated with a Buy at BTIG
BTIG analyst Kambiz Yazdi initiated coverage of Zevra Therapeutics (ZVRA) with a Buy rating and $23 price target Zevra’s current valuation appears to reflect conservative adoption of Miplyffa limited ...
Zevra Therapeutics Transcript: The Citizens Life Sciences Conference 2026
Strong commercial growth and rapid market penetration for MIPLYFFA, with robust diagnosis and persistency rates, are driving expansion in the U.S. and Europe. Strategic investments and disciplined capital allocation support ongoing pipeline development and global access initiatives.
Zevra Therapeutics price target raised to $23 from $22 at Guggenheim
Guggenheim raised the firm’s price target on Zevra Therapeutics (ZVRA) to $23 from $22 and keeps a Buy rating on the shares. Miplyffa’s launch continues to perform well, with FY25…
Zevra Therapeutics Earnings Call Transcript: Q4 2025
Net revenue reached $106.5 million in 2025, driven by MIPLYFFA's strong U.S. and global performance, with 52 annual enrollments and expanding access. Net income swung to $83.2 million, and the company remains well-capitalized for continued growth and pipeline advancement.
Zevra Therapeutics Annual report: Q4 2025
Zevra Therapeutics has published its Q4 2025 annual report on March 9, 2026.
Zevra Therapeutics Earnings release: Q4 2025
Zevra Therapeutics released its Q4 2025 earnings on March 9, 2026, summarizing the period's financial results.
Zevra Therapeutics reports Q4 EPS 20c, consensus 5c
Reports Q4 revenue $34.1M, consensus $28.05M. “Miplyffa is making a meaningful difference for patients with Niemann-Pick disease type C, and its strong, accelerating performance reinforces our confide...
Zevra Therapeutics Slides: Corporate presentation
Zevra Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 9, 2026.
Zevra Therapeutics appoints Renz as Chief Financial Officer
Zevra Therapeutics (ZVRA) announced the appointment of Justin Renz as Chief Financial Officer, effective March 9, 2026. Renz most recently served as Chief Financial & Operations Officer at Ardelyx (AR...
Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call
CELEBRATION, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living wit...